clinical trial · NCT06161116
Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
Merck Sharp & Dohme LLC·phase2·terminated·n = 149
Systemic Lupus ErythematosusMK-6194Placebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with systemic lupus erythematosus.
started
Dec 27, 2023
primary completion
Jul 30, 2025
completion
Jul 30, 2025
last updated
Aug 10, 2026
official title
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol